Infusystem Hld Stock Price, News & Analysis

InfuSystem Holdings, Inc. (NYSE American: INFU), a key provider of outpatient care for durable medical equipment, will participate in Craig-Hallum’s 13th Annual Alpha Select Conference on November 17, 2022, at the Sheraton New York Times Square. CEO Richard DiIorio, CFO Barry Steele, and COO Carrie Lachance will be present for one-on-one meetings. InfuSystem operates under two platforms: Integrated Therapy Services and Durable Medical Equipment Services, serving various healthcare needs across the U.S. and Canada.

InfuSystem Holdings reported record net revenues of $27.3 million for Q3 2022, up 3% year-over-year, with Integrated Therapy Services (ITS) revenues rising to $17.4 million, a 5% increase. Operating income increased by $1.3 million to $0.9 million, with net income of $0.4 million or $0.02 per diluted share. Gross profit also rose to $16.2 million, marking a 6% increase. The company projects full-year revenue at about $112 million, on the lower end of growth guidance of 10% to 13%.

InfuSystem Holdings (INFU) and Sanara MedTech (SMTI) have formed a partnership called SI Wound Care to enhance wound care solutions. This collaboration aims to improve patient outcomes, reduce healthcare costs, and increase satisfaction for both patients and providers. InfuSystem plans to leverage its extensive distribution network as a participating in-network provider for over 95% of the U.S. population. The partnership will include Cork Medical’s negative pressure wound therapy devices and Sanara’s advanced product line, targeting both chronic and acute wounds.

InfuSystem Holdings, Inc. (NYSE American: INFU) announced its third quarter 2022 financial results will be issued on November 8, 2022, before the market opens. A conference call will follow at 9:00 a.m. Eastern Time to discuss the financial outcomes. Interested parties can join by dialing (833) 366-1127 or via a live webcast on the company’s website. InfuSystem provides healthcare services focusing on outpatient care for durable medical equipment manufacturers, with operations across several U.S. states and Canada.

InfuSystem Holdings, Inc. (NYSE American: INFU) appointed R. Rimmy Malhotra as an independent director, effective September 20, 2022. Malhotra, who invested in the company in 2012, brings valuable insights on investments and capital allocation. His appointment is expected to enhance the company’s governance and strategic direction as it aims for long-term growth. Malhotra has extensive experience in investment and management, serving as Vice Chairman of HireQuest Inc. and on various other boards, complementing InfuSystem's focus on outpatient care for durable medical equipment.

InfuSystem Holdings, Inc. (NYSE American: INFU) announced participation in Lake Street Capital Markets' 6th Annual Best Ideas Growth (BIG6) Conference on September 14, 2022, in New York City. CEO Richard DiIorio, CFO Barry Steele, and COO Carrie Lachance will engage in one-on-one and group meetings with investors. The BIG6 Conference is an exclusive event that connects top public companies with institutional investors. InfuSystem specializes in outpatient care and durable medical equipment services, focusing on Integrated Therapy Services and Durable Medical Equipment Services.

InfuSystem Holdings reported Q2 2022 net revenues of $27 million, marking a 9% increase year-over-year. Integrated Therapy Services (ITS) revenues grew 6% to $17.2 million, while Durable Medical Equipment (DME) revenues surged 15% to $9.8 million. Despite revenue growth, gross profit fell 1% to $14.9 million with a gross margin decline to 55.1%. The company posted a net loss of $0.2 million or $(0.01) per diluted share. Adjusted EBITDA was $5.5 million, a 6% decrease. Full-year revenue guidance was revised to 10%-13% growth.

InfuSystem Holdings, Inc. (NYSE American: INFU) has announced the release of its second quarter 2022 financial results on August 4, 2022, before market opening. A subsequent conference call will be held at 9:00 a.m. Eastern Time on the same day to discuss these results. InfuSystem specializes in outpatient care services for durable medical equipment, operating two main platforms: Integrated Therapy Services (ITS) and Durable Medical Equipment Services (DME). Services include oncology, pain management, and more.

InfuSystem Holdings, Inc. (NYSE American: INFU) has announced a national sales and marketing agreement with Ventis Pharma for its Endura-Kit™, a patented local anesthetic compound. This collaboration aims to enhance pain management solutions, focusing on opioid alternatives through multi-modal approaches. The Endura-Kit™ combines three non-opioid drugs, designed to improve post-operative and chronic pain management effectively. This partnership is expected to expand InfuSystem's revenue streams and enhance their service offerings.